Biohaven Therapeutics Ltd.
Clinical trials sponsored by Biohaven Therapeutics Ltd., explained in plain language.
-
Real-World data tests Drug's 3-Year impact on rare brain disorder
Disease control OngoingThis study aims to see if the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disorder that affects movement and coordination, over three years. It compares data from about 909 people who took the drug in a previous long-term study to dat…
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for Tough-to-Treat epilepsy? Long-Term drug safety under the microscope
Disease control ENROLLING_BY_INVITATIONThis study is checking the long-term safety of an experimental drug called BHV-7000 for adults with focal epilepsy that doesn't respond well to current treatments. It's enrolling 660 people worldwide who have already been in a related earlier study. The main goal is to see if peo…
Phase: PHASE2 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Early trial tests new drug for rare, burning pain disorder
Symptom relief ENROLLING_BY_INVITATIONThis early-stage study is testing whether an investigational drug called BHV-7000 can reduce chronic pain in adults with inherited erythromelalgia, a rare genetic disorder that causes severe burning pain. The study will compare the drug to a placebo in a small group of 5 particip…
Phase: PHASE1 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Symptom relief
Last updated Mar 16, 2026 15:25 UTC